, and y interferon (ylFN) inhibit erythropoiesis in vivo and in vitro, and have been implicated in the pathogenesis of the anemia of chronic disease. Anemia in patients with rheumatoid arthritis and in animals exposed chronically to IL-I and TNF can be corrected by the administration of recombinant erythropoietin (Epo). We exposed highly purified human erythroid colonyforming units (CFU-E) cultured from peripheral blood burstforming units-erythroid (BFU-E) and unpurified human marrow CFU-E to recombinant human yIFN and showed inhibition of colony formation in vitro. This inhibition was HE ANEMIA OF chronic disease (ACD) is one of the T most common hematologic syndromes encountered in clinical medicine.' Recent investigations have focussed on the role of mediators of the inflammatory response, such as interleukin-1 (IL-l),233 tumor necrosis factor (TNF),4-6 and y interferon (yIFN),' in the pathogenesis of ACD.
reversed by increased concentrations of Epo. The mechanisms by which this effect occurs are unknown at present. Epo may cause a downregulation of ylFN receptor expression on CFU-E or, alternatively, ylFN may cause a downregulation of Epo receptor expression. A full understanding of these mechanisms awaits a more complete comprehension of the regulation of erythropoiesis; however, the effect of Epo in vitro is similar to its ability to correct the anemia of chronic disease in vivo. This is a US government work. There are no restrictions on its use.
and Nashville Department of Veterans Affairs Medical Center Institutional Review Boards.
rhyIFN (specific activity, 2.5 x lo7 U/mg protein) was purchased from Genzyme Co (Boston, MA).
The method has been reported in detail by Sawada et Briefly, 400 mL of heparinized blood from normal donors was separated over Ficoll-Hypaque (FH; 1.077 g/mL; Pharmacia Fine Chemicals, Picataway, NJ; Winthrop-Breon Laboratories, New York, NY) at 40% for 25 minutes at 24°C. The light density mononuclear cells were collected in a-MEM (Sigma Chemical Co, St Louis, MO), washed, and resuspended in Iscove's modified Dulbecco's medium (IMDM; Sigma). T cells were depleted by sheep erythrocyte rosetting." Adherent cells were then depleted by overnight incubation in 75-cm2 polystyrene tissue culture flasks in IMDM with 20% fetal calf serum (FCS; Hyclone Laboratories, Logan, UT) and 10% giant cell tumor conditioned medium (CM; GIBCO Laboratories, Grand Island, NY) at 37°C in a 5% CO, atmosphere.
After overnight incubation, the nonadherent cells were collected in warm MEM and underwent negative panning with CDllb/ OKM*l, CD2/0KT*11 (Ortho Diagnostic Systems, Raritan, NJ), CD45IMyl1, and CD16/My23, as previously described," to remove colony-forming units granulocyte-macrophage, neutrophils, monocytes, lymphocytes, and natural killer cells. The remaining cells (which typically contain 0.34% BFU-E)" were then cultured at a concentration of 3 x 105/mL in 0.9% methylcellulose (MC; Fisher Scientific Co, Fairlawn, NJ) with 30% FCS, 1% deionized human serum albumin (HSA, American Red Cross Blood Services, Washington, DC), mol/L 2-mercaptoethanol (Eastman Kodak Co, Rochester, NY), penicillin 500 U/mL, streptomycin 40 pg/mL, recombinant human insulin 10 U/mL (Eli Lilly Co, Indianapolis, IN), rhIL-3 50 U/mL (gift of Dr Steven Clark, Genetics Institute, Cambridge, MA), and rhEpo (AmGen Biologicals, Thousand Oaks, CA) 2 U/mL, in 1-mL aliquots distributed into 12-well tissue culture plates (Limbro; Flow Laboratories, Inc, McLean, VA) at 37°C in a high humidity 5% C0,/95% air incubator. After 7 days, the cells were collected in MEM. Debris and residual contaminating cells were then separated from highly purified CFU-E by centrifugation through 10% bovine serum albumin (BSA; Armour Pharmaceutical Co, Kankakee, IL), followed by centrifugation over FH, and adherence in plastic flasks with 20% FCS for 1 hour at 37°C. This process reproducibly yields a 94% viable population of day-8 PB cells, 30% to 90% of which are CFU-E.".l4 The remaining 10% to 70% of cells are polymorphonuclear and basophilic leukocytes.
Six milliliters of BM was aspirated from the posterior iliac crest and collected in an equal volume of IMDM containing 5 U sodium hepariniml. Marrow cells were rhZFN.
Purification of highly purified human CFU-E from PB.
Marrow cell preparation. CFU-E were cultured at concentrations of lo-' PB day-8 cells (highly purified CFU-E)/mL or l@ LDMN marrow cells/mL with IMDM, 15% FCS, 15% pooled human AB serum, 10% HSA or BSA, rhEpo 1 U/mL, penicillin, streptomycin, epsilon aminocaproic acid 1.5 mmol/L, were cultured for 7 days at 37°C in 5% C0,/95% air and then fixed and stained with benzidine-hematoxylin as described by McLeod et aI.l5 Human CFU-E were defined as colonies of 8 to 49 hemoglobinized cells. 16 Each point was studied with three to eight replicates per experiment, and results were normalized to the growth of control plasma clots (cultured without rhyIFN and at an rhEpo concentration of 1 U/mL, expressed as 100%) so that results of different experiments might be compared. The percent CFU-E purity was defined as (number of CFU-E in a clot / D number of cells plated in that clot) x 100. PB day-8 cells were cultured at 200 cells per clot and LDMN marrow cells at 0.2 x lo5 cells per clot. Statistical comparison was by t-test.
RESULTS
Colony formation by highly purified CFU-E (mean purity, 38.1% in three experiments) and unpurified LDMN marrow CFU-E (mean purity, 0.29% in three experiments) was significantly inhibited (P < .001 compared with control) by rhyIFN at all concentrations tested (Table 1) . Colonies resistant to the effect of rhyIFN were not morphologically distinguishable from colonies not exposed to rhy IFN.
The effect of increased concentrations of rhEpo on the inhibition of CFU-E colony formation by rhyIFN was initially studied at an rhyIFN concentration of 100 U/mL. Inhibition of highly purified CFU-E (mean purity, 29.2% CFU-E in three experiments) and LDMN marrow CFU-E (mean purity, 0.29% in three experiments) colony formation by rhyIFN 100 U/mL was overcome by rhEpo (Figs l  and 2 ). This effect was dose-dependent and colony formation at all rhEpo concentrations less than 16 U/mL differed significantly (P < .01) from the control cultures that contained rhEpo 1 U/mL and no rhyIFN. Colonies exposed to higher concentrations of rhEpo did not differ from other colonies morphologically.
Inhibition of CFU-E colony formation by higher concentrations of rhyIFN could also be overcome by rhEpo. Figure 3 shows the effect of increased rhEpo concentrations on the inhibition of LDMN marrow CFU-E colony formation by rhyIFN 1,000 U/mL. Inhibition of CFU-E colony formation is corrected by an rhEpo concentration between 48 U/mL and 100 U/mL. DISCUSSION rhEpo can correct the anemia of patients with rheumatoid arthritis's9 as well as the inhibition of erythropoiesis caused by IL-1 or TNF in vivo3." or in vitro." yIFN, like TNF and IL-1, is associated with inhibition of erythropoiesis in vivo17 and in and we have recently reported that inhibition of CFU-E by IL-1 is mediated by yIFN.I9 Our studies indicate that the inhibition of CFU-E colony formation caused by rhyIFN, like that caused by other cytokines, may be corrected by exposure to higher levels of rhEpo.
Mamus et a17 studied the effect of rhyIFN on CFU-E colony formation from human marrow cells and did not find any correction of inhibition by Epo in cells exposed to r h~1 F N .~ We believe that this finding reflects a difference in experimental design. Mamus et a1 used much higher concentrations of rhyIFN (3,200 and 10,000 U/1.1 mL) and lower (0.5 to 5.0 U/1.1 mL) concentrations of nonrecombinant Epo? We believe that these differences account for the apparent conflict in our results.
The correction of colony formation by highly purified CFU-E or unpurified marrow CFU-E by higher doses of rhEpo does not reflect a compensatory increase in colony formation by additional CFU-E stimulated with increased rhEpo, because maximum colony formation by these CFU-E is obtained at an rhEpo concentration of 1 U/mL.I3 As our results show (confirming earlier reports from this laboratory),13 higher levels of rhEpo do not result in significantly increased colony formation from normal CFU-E. Instead, rhEpo appears to be overcoming an inhibitory process induced in individual CFU-E by rhyIFN.
The mechanism by which rhEpo overcomes the inhibitory effect of rhyIFN remains a topic for speculation. rhEpo may downregulate yIFN receptors on CFU-E, thus reducing the response to the inhibitor. Support for this concept by analogy comes from studies indicating that granulocytemonocyte colony-stimulating factor (GM-CSF) overcomes the inhibitory effect of rhyIFN on human granulocytic progenitors,m and that GM-CSF downregulates yIFN receptor expression on Alternatively, rhyIFN may downregulate Epo receptor expression on CFU-E, with the CFU-E then requiring higher rhEpo concentrations for optimum colony formation. These possible mechanisms can be tested using highly purified CFU-E, and such studies are presently underway in our laboratory. It is also possible that these inhibitory effects may result from alterations in the Epo-stimulated signal transduction pathway, but clarification of this possibility would have to await a more complete understanding of the mode of action of this growth factor.
